CEP-18770 (Delanzomib)

Catalog No. A11145

CEP-18770 (Delanzomib)是一种新型口服活性蛋白酶体抑制剂，IC50为3.8 nM，具有良好的肿瘤选择性，可用于治疗对蛋白酶体抑制有反应的MM和其他恶性肿瘤。

Technical details

Catalog Num	A11145
M. Wt	413.3
Formula	C21H28BN3O5
Purity	>98%
Storage	at -20°C 3 years Powder
CAS No.	847499-27-8
Synonyms	CEP18770
SMILES	B([C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)C1=CC=CC(=N1)C2=CC=CC=C2)(O)O

Biological Activity

CEP-18770 (Delanzomib)是一种新型口服活性蛋白酶体抑制剂，IC50为3.8 nM，具有良好的肿瘤选择性，可用于治疗对蛋白酶体抑制有反应的MM和其他恶性肿瘤。

Targets

Chymotrypsin-like proteasome
3.8 nM

Solubility *

In vitro	DMSO	73 mg/mL (176.63 mM)
	Water	Insoluble
	Ethanol	73 mg/mL (176.63 mM)
* <1 mg/ml means slightly soluble or insoluble. * Please note that Adooq tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Preparing Stock Solutions

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
0.1 mM	24.2 mL	120.98 mL	241.95 mL
0.5 mM	4.84 mL	24.2 mL	48.39 mL
1 mM	2.42 mL	12.1 mL	24.2 mL
5 mM	0.48 mL	2.42 mL	4.84 mL

*The above data is based on the productmolecular weight 413.3 . Batch specific molecular weights may vary from batch to batch due to solvent of hydration, which will affect the solvent volumes required to prepare stock solutions.